AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38861793
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium (shake with 6.4 mg Ca/day)
Trial: 38861793
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups on energy-restricted diets (-500 kcal/d, 800 mg of dietary Ca/d)
Trial: 38862179
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (ticagrelor 90 mg twice daily plus aspirin 100 mg once daily)
Trial: 38862179
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy (90 mg twice daily)
Trial: 38862251
Drug: Neoadjuvant toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant toripalimab 240 mg every 3 weeks (three cycles) combined with axitinib 5 mg twice daily for up to 12 weeks.
Trial: 38862308
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care plus peer-led vaccine counseling
Trial: 38862815
Drug: Self-administered mindfulness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered mindfulness interventions
Trial: 38862908
Drug: Anlotinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (12 mg/day orally for 14 days on and 7 days off) and nivolumab (360 mg every 3 weeks)
Trial: 38863026
Drug: Hydrogen-oxygen gas
RxNorm normalized name: oxygen Gas for Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-oxygen gas mixture inhalation (8 hours per day, 3 L/min, hydrogen concentration of 67%, oxygen concentration of 33%)
Trial: 38863026
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation (8 hours per day, 3 L/min, oxygen concentration of 33%)
Trial: 38863155
Drug: Fidanacogene elaparvovec
RxNorm normalized name: Fidanacogene elaparvovec
DrugBank: Fidanacogene elaparvovec (DB16783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fidanacogene elaparvovec (gene therapy)
Trial: 38863591
Drug: Immunomodulatory formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory formula with extra virgin olive oil (administered 5 days before surgery)
Trial: 38863672
Drug: Intensive inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive inpatient trauma treatment program with prolonged exposure (PE), eye movement desensitization and reprocessing (EMDR), and therapist rotation (TR)
Trial: 38863672
Drug: Intensive inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive inpatient trauma treatment program
Trial: 39233711
Drug: Fostemsavir +
RxNorm normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostemsavir + optimized background therapy
Trial: 38864524
Drug: HIL-214 (formerly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIL-214 (formerly TAK-214) vaccine
Trial: 38864600
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 300 mg b.i.d. plus 1.2 mg midazolam (MDZ) on Days 11 and 14
Trial: 38864600
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 300 mg b.i.d. alone on Days 8-10
Trial: 38864600
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 200 mg b.i.d. alone on Days 5-7
Trial: 38864600
Drug: Midazolam (MDZ)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam (MDZ) 1.2 mg alone on Day 1
Trial: 38864600
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 300 mg b.i.d. on Days 11 and 14
Trial: 38864969
Drug: Intralipid 20%
RxNorm normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid 20% (1.5 ml/kg) administered 3 min before aortic cross unclamping
Trial: 38864969
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's Lactate (control group) administered 3 min before aortic cross unclamping
Trial: 38865064
Drug: Zinc-vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc-vitamin E group (n = 40) received oral zinc (120 mg) and vitamin E (1200 IU) before surgery, followed by 30 mg of zinc and 200 IU of vitamin E daily until 21 days after surgery.
Trial: 38865084
Drug: Maternal immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal immune responses to CMV, including anti-pentamer immunoglobulin G antibody concentration and viral load in saliva.
Trial: 38865129
Drug: Limosilactobacillus reuteri
RxNorm normalized name: Limosilactobacillus reuteri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limosilactobacillus reuteri high dose (5×10^9 CFU)
Trial: 38865129
Drug: Limosilactobacillus reuteri
RxNorm normalized name: Limosilactobacillus reuteri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limosilactobacillus reuteri low dose (5×10^8 CFU)
Trial: 38865168
Drug: Intravenous amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amino acids (2 g per kilogram of ideal body weight per day)
Trial: 38865168
Drug: Intravenous amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amino acids
Trial: 38865296
Drug: Clinical practices
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical practices and interventions (e.g., warm compresses, manual perineal protection, vaginal examinations, perineal massage, levator pressure, intermittent catheterization, fundal pressure, episiotomy)
Trial: 38865704
Drug: Web-based therapist-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based therapist-guided mindfulness-based cognitive behavioral therapy (CBT-M)
Trial: 38865704
Drug: Web-based therapist-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based therapist-guided cognitive behavioral therapy (CBT)
Trial: 38866072
Drug: Minnelide 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minnelide 1.5 mg as monotherapy (Regimen A)
Trial: 38866072
Drug: Minnelide 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minnelide 1.25 mg once daily for 21 days Q4 weeks as monotherapy (MTD)
Trial: 38866072
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Minnelide plus paclitaxel (Regimen B & C)
Trial: 38866095
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available treatment without ANH
Trial: 38866559
Drug: PENG block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PENG block (20 mL of 0.3% ropivacaine)
Trial: 38866559
Drug: SIFICB (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIFICB (30 mL of 0.3% ropivacaine)
Trial: 38866567
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) in addition to usual care (UC)
Trial: 38866575
Drug: Internet-based individual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based individual therapy for insomnia (iCBT-I) + TAU
Trial: 38866575
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy for insomnia (GCBT-I) + TAU
Trial: 38866822
Drug: CAR T
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR T cell therapy (as referenced in the BNT-211-01 trial, NCT04503278)
Trial: 38867006
Drug: Yttrium-90-anti-CD66 antibody
RxNorm normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yttrium-90-anti-CD66 antibody
Trial: 38867018
Drug: HFNC flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC flow 30 l/min, open mouth
Trial: 38867018
Drug: HFNC flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC flow 30 l/min, closed mouth
Trial: 38867018
Drug: HFNC flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC flow 70 l/min, open mouth
Trial: 38867018
Drug: HFNC flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC flow 70 l/min, closed mouth
Trial: 38867018
Drug: 95% Limits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95% Limits of Agreement for 30 l/min - closed mouth
Trial: 38867018
Drug: 95% Limits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95% Limits of Agreement for 30 l/min - open mouth
Trial: 38867018
Drug: 95% Limits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95% Limits of Agreement for 70 l/min - closed mouth
Trial: 38867018
Drug: 95% Limits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95% Limits of Agreement for 70 l/min - open mouth
Trial: 38867164
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy protocols
Trial: 38867164
Drug: Broad-spectrum antibiotic
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antibiotic therapy ≥ 4 days
Trial: 38867164
Drug: Prescribing ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribing ≥ 2 antibiotics
Trial: 38867195
Drug: Bowen's Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowen's Therapy
Trial: 38867220
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) - primarily herbal medicine (HM)
Trial: 38867257
Drug: Tunlametinib 9
RxNorm normalized name: Tramétinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tunlametinib 9 mg plus vemurafenib 720 mg, twice daily (BID)
Trial: 38867309
Drug: Intensive Prolonged
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Prolonged Exposure (iPE) therapy
Trial: 38867309
Drug: Standard weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weekly delivered sessions of Prolonged Exposure (PE) therapy
Trial: 38867317
Drug: Personalized music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized music therapy (MT) for at least 2 hours per day
Trial: 38867317
Drug: Generalized music
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generalized music therapy (MT) for 12.5 hours per day, subdivided into fifteen 50-min periods
Trial: 38867317
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without music therapy (MT)
Trial: 38867317
Drug: Generalized music
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generalized music therapy (MT)
Trial: 38867349
Drug: Trametinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (oral MEK1/2 inhibitor), administered for a maximum of 12 cycles.
Trial: 38867582
Drug: Azacitidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (5 days treatment prior to chemotherapy)
Trial: 38869701
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at 0.025 µg/kg/min
Trial: 38869701
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at 0.05 µg/kg/min
Trial: 38869701
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at 0.075 µg/kg/min
Trial: 38869746
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg orally BID plus celecoxib 200 mg orally once daily for 12 weeks
Trial: 38869746
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets BID plus celecoxib 200 mg orally once daily for 12 weeks
Trial: 38869771
Drug: Talazoparib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib monotherapy
Trial: 38869865
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of TKI treatment and follow-up every 3 months.
Trial: 38869865
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to next treatment.
Trial: 38869931
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (transfusions initiated at hemoglobin level ≤10 g/dL)
Trial: 38869931
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (transfusions initiated at hemoglobin level ≤7 g/dL)
Trial: 38869978
Drug: Antidepressants (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (specific mention of paroxetine and sertraline)
Trial: 38869987
Drug: Avenciguat 1
RxNorm normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenciguat 1 mg twice-daily
Trial: 38869987
Drug: Avenciguat 2
RxNorm normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenciguat 2 mg twice-daily
Trial: 38869987
Drug: Avenciguat 3
RxNorm normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenciguat 3 mg twice-daily
Trial: 38870076
Drug: Conventional diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diabetes treatments
Trial: 38870103
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Norepinephrine)
Trial: 38870156
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment as usual
Trial: 38870749
Drug: Qilong capsule
RxNorm normalized name: TOCOPHEROL 1 g in 99 g TOPICAL CREAM [Guangzhou Yilong Cosmetics Co., Ltd]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qilong capsule (QLC) combined with conventional treatment (CT)
Trial: 38870749
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (CT) alone
Trial: 38870931
Drug: Serplulimab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab (300 mg) plus HLX04 (7.5 mg/kg) and XELOX
Trial: 38870931
Drug: Placebo (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (300 mg) plus bevacizumab (7.5 mg/kg) and XELOX
Trial: 38870977
Drug: Nanoliposomal irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoliposomal irinotecan (70 mg/m²) plus fluorouracil plus leucovorin
Trial: 38871657
Drug: Tacrolimus 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.02 mg/kg intravenous infusion over 4 hours prior to organ retrieval
Trial: 38872109
Drug: Dose-matched PT
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched PT sessions
Trial: 38872193
Drug: Diet +
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet + Supplementation: individualized diet supplemented with 604 mg of omega-3 fatty acids, three times a day
Trial: 38872193
Drug: Diet +
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet + Placebo: individualized diet + 1 g of soybean oil
Trial: 38872193
Drug: Placebo: 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 1 g of soybean oil daily, no dietetic intervention
Trial: 38872204
Drug: Low-intensity intervention
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity intervention group (bi-monthly online lifestyle-related health advice)
Trial: 38872994
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg/day
Trial: 38873632
Drug: Upadacitinib 6
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib 6 mg (UPA6)
Trial: 38873632
Drug: Upadacitinib 11
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib 11 mg (UPA11)
Trial: 38873632
Drug: Upadacitinib 22
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib 22 mg (UPA22)
Trial: 38873634
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TRAN) - 1-g slow intravenous infusion within 5 minutes from childbirth
Trial: 38873723
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg) plus standard care
Trial: 38873885
Drug: Adjunctive azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive azithromycin (500 mg)
Trial: 38873934
Drug: vemurafenib at
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib at 550 mg/m2 (maximum 960 mg/dose) orally twice daily for 28-day cycles
Trial: 38874333
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ipilimumab and Nivolumab (IPI + NIVO)
Trial: 38874333
Drug: Control (Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Standard treatment)
Trial: 38875119
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa (BA) plus GemCis (gemcitabine 1000 mg/m2 + cisplatin 25 mg/m2 on days 1 and 8 every 3 weeks for 8 cycles)
Trial: 38875119
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus GemCis (gemcitabine 1000 mg/m2 + cisplatin 25 mg/m2 on days 1 and 8 every 3 weeks for 8 cycles)
Trial: 38875121
Drug: Long-acting dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting dexamethasone viscous gel delivered by transforaminal injection
Trial: 38875111
Drug: Intravenous pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pantoprazole (40 mg daily)
Trial: 38875279
Drug: LUNA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUNA treatment delivered twice weekly for 10 weeks via videoconferencing (Zoom)
Trial: 38875279
Drug: LUNA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUNA treatment
Trial: 38875579
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) models using weekly and daily DPP data sets (328,821 and 704,242 records)
Trial: 38875880
Drug: Office-based addiction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based addiction treatment (OBAT)
Trial: 38876647
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy interventions (MTIs) including passive joint mobilisation and soft tissue manipulation, administered for eight weekly 30-min sessions.
Trial: 38876647
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy interventions (MTIs)
Trial: 38877077
Drug: Happy Mother-Healthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Happy Mother-Healthy Baby program (Cognitive Behavior Therapy)
Trial: 38877450
Drug: Laparoscopic resection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic resection rectopexy (L-RRP) with mesh-sacrocolpopexy (L-SCP) using synthetic mesh (SM)
Trial: 38877450
Drug: Laparoscopic resection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic resection rectopexy (L-RRP) with mesh-sacrocolpopexy (L-SCP) using biological mesh (BM)
Trial: 38877571
Drug: Haemoglobin values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoglobin values < 7.5 g/dL
Trial: 38877571
Drug: Haemoglobin values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoglobin values between 7.5-9.5 g/dL